Focused on the road ahead
Our hunger to keep progressing and deliver what patients need from science keeps us focused on what matters. We are embracing the challenge to transform our science and ourselves.
About Us
Discoveries in science and technology mean our knowledge of diseases has grown to the point where more people enjoy an enhanced quality of life than ever before. True progress has been made, yet the mission is far from complete—especially for those living with unmet medical needs. At Dompé, we push the boundaries of science and pursue research and development in new and unexpected areas to positively impact patients’ lives
A Legacy of Science, A Future of Innovation
Dompé farmaceutici S.p.A. is the parent company of the Dompé operating companies, with headquarters in Milan, Italy. We are an international biopharmaceutical company active across the entire pharmaceutical value chain, from research to development, production and commercialization. Our journey began as Milan’s first compounding pharmacy and has grown into a global organization. As a long-established family company, we blend the stability of our 130-year heritage with the agility and dynamism of a biotech innovator.
Employees
950
Sales in millions of euros (2024)
1.234
Millions of packaging manufactured (2020)
60
Production lines (8 synthesis, 1 biotech)
9
Biotech Approvals
Therapeutic Areas
Ophthalmology, Neurology and Pain
Reach
Europe, United States, China
CDMO
Synthesis and biotech
Innovative research leads to novel treatments
In the pursuit of improving human health, our R&D strives to break through in new scientific territories. This is what led us to Nerve Growth Factor (NGF), a Nobel Prize‑winning discovery made in 1986. We leveraged 50 years of research to transform this breakthrough into the first approved treatment for a rare degenerative eye disease. That deep appreciation of science continues to drive our investigation of neurotrophins.
Harnessing technology to accelerate drug discovery
Our dedicated commitment to developing new treatments for disease has led us to harness the potential of bioinformatics to accelerate the drug discovery process. The result is Exscalate, a structure‑based virtual screening platform developed in‑house and presently one of the most powerful supercomputing and artificial intelligence platforms for drug testing. It is the most extensive enumerated chemical library in the world for preclinical and clinical candidate identification.
Our production hub is the heart of Dompé
We transform scientific breakthroughs into treatments thanks to the expertise and capabilities that drive new drug development. Our 170,000‑square‑meter R&D and production site in L’Aquila, Italy, stands as the true heart of Dompé—where vital research is carried out and our Primary Care and Biotech products are produced and distributed worldwide.
We value our people
People are our most valuable asset. Driven by a passion to make a meaningful difference in patients’ lives, we move forward with purpose. In fulfilling our mission, we uphold the highest ethical standards, act with integrity, and remain attentive to the voices of patients. Equally, we are committed to collaborating with the scientific community to unlock the full potential of drug and technology innovation, transforming discoveries into life‑changing treatments.
Responsibility
At Dompé, we are dedicated to enhancing and maintaining the highest levels of ethics, integrity, and transparency in everything we do in compliance with laws and regulations. In addition, We keep pushing the frontiers of science in our relentless pursuit of producing safe, effective drugs to make a meaningful difference in patients’ lives.
It’s this responsible behavior that guides us. We adhere scrupulously to ethical principles, comply with many different regulatory systems, and operate with the highest integrity and transparency. All while remaining fully committed to lowering our environmental impact and ensuring our employees work in an environment where health and safety are paramount.
Explore More
Exscalate
The discovery of new drug molecules is pivotal to identifying novel therapeutic strategies. But drug discovery is a slow and articulated process with an extremely high failure rate. At Dompé, we have developed the virtual screening platform Exscalate to accelerate the drug screening process.